Equities research analysts expect Dimension Therapeutics, Inc. (NASDAQ:DMTX) to post earnings per share of ($0.49) for the current quarter, Zacks reports. Zero analysts have made estimates for Dimension Therapeutics’ earnings. Dimension Therapeutics also reported earnings per share of ($0.49) in the same quarter last year. The company is expected to announce its next quarterly earnings report on Thursday, August 10th.
According to Zacks, analysts expect that Dimension Therapeutics will report full-year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.26) to ($1.99). For the next year, analysts forecast that the business will report earnings of ($1.44) per share, with EPS estimates ranging from ($2.20) to ($0.67). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Dimension Therapeutics.
Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.02. Dimension Therapeutics had a negative return on equity of 80.04% and a negative net margin of 412.27%. The firm had revenue of $3.62 million during the quarter.
A number of research analysts recently issued reports on the company. Cantor Fitzgerald set a $3.00 target price on Dimension Therapeutics and gave the company a “hold” rating in a report on Saturday, June 10th. Zacks Investment Research upgraded Dimension Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Tuesday, April 18th. Citigroup Inc. lowered Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 target price for the company. in a report on Friday, May 12th. Finally, Canaccord Genuity decreased their target price on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Dimension Therapeutics has an average rating of “Hold” and a consensus target price of $5.88.
Hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in Dimension Therapeutics during the first quarter worth approximately $108,000. Renaissance Technologies LLC purchased a new stake in Dimension Therapeutics during the fourth quarter worth approximately $236,000. Finally, Weiss Multi Strategy Advisers LLC boosted its stake in Dimension Therapeutics by 6.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock worth $683,000 after buying an additional 24,489 shares during the period. Institutional investors own 74.59% of the company’s stock.
Dimension Therapeutics (NASDAQ DMTX) traded down 3.45% on Thursday, hitting $1.40. The stock had a trading volume of 17,508 shares. The company’s market cap is $35.06 million. Dimension Therapeutics has a 52-week low of $1.05 and a 52-week high of $9.98. The firm’s 50-day moving average is $1.33 and its 200-day moving average is $1.87.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Get a free copy of the Zacks research report on Dimension Therapeutics (DMTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
